Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) have received a consensus rating of “Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $4.82.

CATB has been the subject of a number of research reports. CIBC reissued an “outperform” rating and set a $7.00 price target (up from $4.00) on shares of Catabasis Pharmaceuticals in a research note on Thursday, October 5th. Zacks Investment Research raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Thursday, November 16th. Oppenheimer dropped their price target on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research note on Tuesday, August 15th. Citigroup reissued a “hold” rating and set a $1.50 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, September 29th. Finally, Cowen reissued a “market perform” rating and set a $2.00 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, October 6th.

Shares of Catabasis Pharmaceuticals (CATB) opened at $1.71 on Thursday. Catabasis Pharmaceuticals has a 1 year low of $1.08 and a 1 year high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. The firm had revenue of $0.25 million for the quarter. equities analysts predict that Catabasis Pharmaceuticals will post -1.39 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. lifted its stake in shares of Catabasis Pharmaceuticals by 33.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 30,000 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter valued at approximately $106,000. Virtu KCG Holdings LLC bought a new stake in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at approximately $271,000. Finally, Wedbush Securities Inc. lifted its stake in shares of Catabasis Pharmaceuticals by 2,368.6% in the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after purchasing an additional 241,602 shares during the last quarter. 33.14% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Catabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of “Buy” from Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/07/catabasis-pharmaceuticals-inc-catb-receives-average-recommendation-of-buy-from-analysts.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.